Australia's most trusted
source of pharma news
Posted 14 February 2025 AM
Vertex is yet to reveal whether it will branch out from the lucrative cystic fibrosis (CF) market and bring its pain treatment Journavx, which has been labelled one of the biggest potential launches of 2025 to Australia.
The hyped non-opioid pain treatment, also known as suzetrigine, was approved by the FDA this month to treat moderate to severe acute pain. Around 80 million people in America are prescribed a medicine for moderate to severe acute pain each year, according to Vertex CEO, Reshma Kewalramani.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.